Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

Wick, Wolfgang; Platten, Michael; Meisner, Christoph; Felsberg, Joerg; Tabatabai, Ghazaleh; Simon, Matthias; Nikkhah, Guido; Papsdorf, Kirsten; Steinbach, Joachim P.; Sabel, Michael; Combs, Stephanie E.; Vesper, Jan; Braun, Christian; Meixensberger, Juergen; Ketter, Ralf; Mayer-Steinacker, Regine; Reifenberger, Guido; Weller, Michael

doi:10.1016/s1470-2045(12)70164-x

Cited by 1,015 publications

(647 citation statements)

References 30 publications

Supporting

Mentioning

602

Contrasting

Unclassified

Order By: Relevance

“…A famous example of a clinical biomarker to predict response to temozolomide in gliomas is the inactivation by promoter hypermethylation of the O6-methylguanine-DNA methyl-transferase-encoding (MGMT) gene in samples from patients with GBM. [43][44][45][46] Importantly, part of The Cancer Genome Atlas (TCGA) studies focused on examining the genomic and epigenomic modifications occurring in GBM. These studies, applying genome-wide DNA methylation profiling in an adult patient cohort, led to the identification of a G-CIMP positive group associated with isocitrate dehydrogenase 1 (IDH1) mutations, and hypermethylation at a large number of loci was linked to a less severe outcome.…”

Section: High-grade Gliomamentioning

confidence: 99%

Epigenetic modification in chromatin machinery and its deregulation in pediatric brain tumors: Insight into epigenetic therapies

Maury

Hashizume

2017

Epigenetics

View full text Add to dashboard Cite

Malignancies are characterized by the reprogramming of epigenetic patterns. This reprogramming includes gains or losses in DNA methylation and disruption of normal patterns of covalent histone modifications, which are associated with changes in chromatin remodeling processes. This review will focus on the mechanisms underlying this reprogramming and, specifically, on the role of histone modification in chromatin machinery and the modifications in epigenetic processes occurring in brain cancer, with a specific focus on epigenetic therapies for pediatric brain tumors.

show abstract

Section: High-grade Gliomamentioning

confidence: 99%

Epigenetic modification in chromatin machinery and its deregulation in pediatric brain tumors: Insight into epigenetic therapies

Maury

Hashizume

2017

Epigenetics

View full text Add to dashboard Cite

show abstract

“…For elderly patients, e.g., older than 65-70 years, the standard of care for newly diagnosed glioblastoma without MGMT promoter methylation or unknown MGMT status is radiotherapy alone [4]. In contrast, elderly patients with glioblastoma with MGMT promoter methylation should receive TMZ without or with radiotherapy [5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Therapeutic options in recurrent glioblastoma—An update

Seystahl

Wick

Weller

2016

Critical Reviews in Oncology/Hematology

Self Cite

179

134

View full text Add to dashboard Cite

show abstract

“…Although a few trials since then have included older patients, 17,18 the focus those trials has been on the application of adjuvant therapy after nondefinitive, attempted or completed gross total resection of tumor. It has been demonstrated that gross total resection has a survival advantage compared with partial resection and certainly compared with biopsy alone.…”

Section: Interpretations In the Context Of The Literaturementioning

confidence: 99%

Short‐term outcomes of craniotomy for malignant brain tumors in the elderly

Seicean

Schiltz

et al. 2012

Cancer

View full text Add to dashboard Cite

BACKGROUND. Disparity in resection rates for malignant brain tumors in elderly patients is partially attributed to a belief that advanced age is associated with an increased risk of postoperative morbidity and mortality. The objective of this study was to investigate the effect of advanced age (!75 years) on 30-day outcomes in patients with primary and metastatic brain tumors who underwent craniotomy for definitive resection of a malignant brain tumor. METHODS. The authors conducted prospective analyses of the American College of Surgeons' National Surgical Quality-Improvement Project (NSQIP) database from 2006 to 2010 of 970 patients aged !40 years who underwent craniotomy for definitive resection of neoplasm. Preoperative and intraoperative characteristics and 30-day outcomes were stratified by age. By using propensity scores, 134 patients (aged !75 years) were matched to 134 patients ages 40 to 74 years. Logistic regression was used to predict adverse postoperative outcomes. RESULTS. The median length of hospital stay was 5 days; the rate of minor and major complications were 5.9% and 13.1%, respectively; 5.7% of patients returned to the operating room; and 4.3% of patients died within 30 days. Advanced age did not increase the odds for poorer short-term outcomes. CONCLUSIONS. Advanced age did not increase the risk of poor outcomes after surgical resection of primary or metastatic intracranial tumors when analyses were controlled for other risk factors. These results suggest that age should not be used, in isolation, as an a priori factor to discourage pursuing craniotomy.

show abstract

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

Cited by 1,015 publications

References 30 publications

Epigenetic modification in chromatin machinery and its deregulation in pediatric brain tumors: Insight into epigenetic therapies

Epigenetic modification in chromatin machinery and its deregulation in pediatric brain tumors: Insight into epigenetic therapies

Therapeutic options in recurrent glioblastoma—An update

Short‐term outcomes of craniotomy for malignant brain tumors in the elderly

Contact Info

Product

Resources

About